Get the Stockscreener App
1.40
2.78%
-0.04
Marker Therapeutics Inc stock is traded at $1.40, with a volume of 116.64K.
It is down -2.78% in the last 24 hours and down -15.66% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.44
Open:
$1.43
24h Volume:
116.64K
Relative Volume:
0.35
Market Cap:
$23.18M
Revenue:
$4.70M
Net Income/Loss:
$-14.30M
P/E Ratio:
-1.1391
EPS:
-1.229
Net Cash Flow:
$-14.82M
1W Performance:
-11.39%
1M Performance:
-15.66%
6M Performance:
+56.11%
1Y Performance:
-23.91%
1-Day Range:
$1.3501
$1.4859
1-Week Range:
$1.32
$1.5993
52-Week Range:
$0.8099
$4.07
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.39 | 24.01M | 4.70M | -14.30M | -14.82M | -1.229 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
MRKR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MRKR: First-in-class MAR-T cell therapy shows high efficacy and safety in refractory lymphoma - TradingView
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
How buybacks impact Marker Therapeutics Inc. stock value2025 Top Decliners & AI Based Buy/Sell Signal Reports - mfd.ru
Is Marker Therapeutics Inc. stock a safe buy before earningsMarket Weekly Review & Fast Moving Stock Trade Plans - mfd.ru
Marker Therapeutics sets date for 2026 annual shareholder meeting and proposal deadline - Investing.com Nigeria
Marker Therapeutics Sets Date for 2026 Annual Meeting - TipRanks
Portfolio Update: Why is Mattel Inc stock going upJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Can BioSig Technologies Inc benefit from deglobalizationPortfolio Performance Report & Safe Entry Trade Reports - baoquankhu1.vn
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology - manilatimes.net
Good Morning America puts Baylor T-cell cancer trial in national spotlight - Stock Titan
Good Morning America Features Baylor College of Medicine - GlobeNewswire
Institution Moves: Should I trade or invest in One Liberty Properties IncJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
MRKR stock up nearly 114% in 3 months: Here's what you need to know - MSN
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Risk Analysis: Can Marker Therapeutics Inc outperform in the next rallyJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-20 15:10:37 - baoquankhu1.vn
Whale Trades: Does REBN have consistent dividend growthTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) Cut to “Hold” at Zacks Research - Defense World
Jobs Data: Can PGHL disrupt its industryLayoff News & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Bearish Setup: Is Marker Therapeutics Inc a strong candidate for buy and holdJuly 2025 Final Week & AI Enhanced Trading Signals - baoquankhu1.vn
Is Marker Therapeutics Inc. on track to beat earningsPortfolio Update Report & Weekly Watchlist of Top Performers - bollywoodhelpline.com
High Growth Tech Stocks To Watch In The US Market January 2026 - simplywall.st
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - simplywall.st
Insider Trends: Will Marker Therapeutics Inc. stock benefit from commodity pricesWeekly Investment Recap & Low Risk Profit Maximizing Plans - Улправда
How sustainable is Marker Therapeutics Inc. stock dividend payout2025 Year in Review & Safe Capital Growth Plans - Улправда
Short Interest Drops in Twinstar Industries Limited After RallyJuly 2025 Opening Moves & Low Volatility Stock Suggestions - Улправда
Will Marker Therapeutics Inc. stock benefit from green energy trendsSell Signal & Real-Time Chart Pattern Alerts - Улправда
How strong is Marker Therapeutics Inc. stock balance sheetWeekly Risk Report & Stepwise Entry and Exit Trade Signals - Улправда
Will NEXT plc (NXG) stock gain from green policiesJuly 2025 Earnings & Intraday High Probability Setup Alerts - Улправда
Can Marker Therapeutics Inc. stock sustain market leadership2025 Investor Takeaways & AI Powered Buy/Sell Recommendations - Улправда
Why Marker Therapeutics Inc. (GX1) stock could rally stronglyDay Trade & Verified High Yield Trade Plans - Улправда
Will Marker Therapeutics Inc. stock benefit from commodity pricesTrade Volume Report & Free Community Consensus Stock Picks - Улправда
Why Marker Therapeutics Inc. stock remains on buy listsJuly 2025 Earnings & Fast Exit and Entry Trade Guides - Улправда
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Breakouts Watch: How strong is Marker Therapeutics Inc. stock balance sheetWeekly Loss Report & Fast Entry High Yield Stock Tips - Bộ Nội Vụ
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy? - sharewise.com
Marker Therapeutics, Inc. (MRKR) now trades above golden cross: Time to buy? - MSN
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer - MSN
Marker Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Is Marker Therapeutics Inc GX1 a good long term investmentMarket Sentiment Shifts & Buy Sell Signal Notifications - earlytimes.in
สล็อต www.mio555.com - earlytimes.in
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Brookline Capital raises Marker Therapeutics stock price target to $5.60 By Investing.com - Investing.com Canada
Marker Therapeutics Reports Positive Phase 1/2 Clinical Study Results for Multi-Antigen Targeted T Cells in Pancreatic Cancer Patients - Quiver Quantitative
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer - The Manila Times
Baylor College of Medicine Publishes Promising Safety and - GlobeNewswire
Wall Street Zen Upgrades Marker Therapeutics (NASDAQ:MRKR) to Hold - Defense World
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Why Marker Therapeutics Inc stock remains undervaluedMarket Trend Review & Verified Stock Trade Ideas - moha.gov.vn
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):